Crystallization of IGF-1

Details Crystallization of IGF-1 Crystallization of IGF-1

2006-06-20

2008-10-07

Steadman, David J. (Department: 1656)

Data processing: measuring, calibrating, or testing

Measurement system in a specific environment

Chemical analysis

C436S086000, C436S004000, C530S303000, C703S011000

Reexamination Certificate

active

07433788

ABSTRACT:
Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method for identifying IGF-1 indirect agonists is provided using a detergent as a standard for the level of inhibition of binding of IGFBP-1 or IGFBP-3 to IGF-1 and/or using the coordinates of the binding pockets of IGF-1 to which a candidate indirect agonist binds for structure-based drug design.

REFERENCES:
patent: 4672108 (1987-06-01), Kung et al.
patent: 4833233 (1989-05-01), Carter
patent: 4876242 (1989-10-01), Applebaum et al.
patent: 4959351 (1990-09-01), Grau
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5028587 (1991-07-01), Dorschug et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5202119 (1993-04-01), Clark et al.
patent: 5273961 (1993-12-01), Clark
patent: 5374620 (1994-12-01), Clark et al.
patent: 5461031 (1995-10-01), De Felippis
patent: 5466670 (1995-11-01), Dunger et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5504188 (1996-04-01), Baker et al.
patent: 5534488 (1996-07-01), Hoffmann
patent: 5547930 (1996-08-01), Balschmidt
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5597893 (1997-01-01), Baker et al.
patent: 5650486 (1997-07-01), De Felippis
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 5747642 (1998-05-01), De Felippis
patent: 5834422 (1998-11-01), Balschmidt
patent: 5840680 (1998-11-01), Balschmidt
patent: 5898028 (1999-04-01), Jensen et al.
patent: 5898067 (1999-04-01), Balschmidt et al.
patent: 5948751 (1999-09-01), Kimer et al.
patent: 5952297 (1999-09-01), De Felippis et al.
patent: 6127334 (2000-10-01), Kimer et al.
patent: 668914 (1995-08-01), None
patent: 91/03253 (1991-03-01), None
patent: WO 91/03253 (1991-03-01), None
patent: 92/11865 (1992-07-01), None
patent: WO 92/11865 (1992-07-01), None
patent: 93/08826 (1993-05-01), None
patent: WO 93/08826 (1993-05-01), None
patent: 93/23067 (1993-11-01), None
patent: 93/23071 (1993-11-01), None
patent: WO 93/23067 (1993-11-01), None
patent: WO 93/23071 (1993-11-01), None
patent: 93/25219 (1993-12-01), None
patent: WO 93/25219 (1993-12-01), None
patent: WO 94/04569 (1994-03-01), None
patent: WO 94/16722 (1994-08-01), None
patent: WO 96/01124 (1996-01-01), None
patent: WO 96/33216 (1996-10-01), None
patent: WO 97/00895 (1997-01-01), None
patent: WO 98/45427 (1998-10-01), None
patent: WO 99/01476 (1999-01-01), None
patent: WO 99/38011 (1999-07-01), None
patent: 00/23469 (2000-04-01), None
patent: WO 00/23469 (2000-04-01), None
patent: WO 01/72771 (2001-10-01), None
patent: 02/098914 (2002-12-01), None
Cook et al. Protein Data Bank, accession No. 2GF1 Jan. 23, 1991.
Cook et al. Protein Data Bank, accession No. 3GF1 Jan. 24, 1991.
Cohen et al. Molecular modeling software and methods for medicinal chemistry. J. Med. Chem. 33 (3), 883-894.
Wiencek et al. New strategies for protein crystal growth. Ann. Rev. Biomed. Eng. 1999, 1, 505-534.
Ke et al. Crystallization of RNA and RNA-protein complexes. Methods 34, 2004, 408-414.
Adams et al., “Structure of Rhombohedral 2 Zinc Insulin Crystals.”Nature. 224:491-495 (Nov. 1969).
Bach and Rechler., “Insulin-Like Growth Factor Binding Proteins.”Diabetes Reviews. 3(1):38-61 (1995).
Baker et al., “Role of Insulin-Like Growth Factors in Embryonic and Postnatal Growth.”Cell. 75:73-82 (Oct. 1993).
Ballard et al., “Does IGF-I Ever Act Through the Insulin Receptor?”The Insulin-Like Growth Factors and Their Regulatory Proteins., Baxter, eds., Amsterdam: Elsevier pp. 131-138 (1994).
Bar et al., “Tissue Localization of Perfused Endothelial Cell IGF Binding Protein is Markedly Altered b Association with IGF-I.”Endocrinology. 127(6):3243-3245 (1990).
Barinaga, M., “Neurotrophic Factors Enter the Clinic [News].”Science. 264:772-774 (1994).
Baserga., “The Insulin-Like Growth Factor 1 Receptor: A Key to Tumor Growth?”Cancer Research55:249-25 (Jan. 1995).
Baxter, “Physiological Roles of IGF Binding Proteins”Modern Concepts of Insulin-like Growth Factors, Spencer, eds., Elsevier, New York pp. 371-380 (1991).
Baxter., “The Somatomedins: Insulin-Like Growth Factors.”Advances in Clinical Chemistry. 25:49-115 (1986).
Bayne et al., “Structural Analogs of Human Insulin-Like Growth Factor I with Reduced Affinity for Serum Binding Proteins and the Type 2 Insulin-Like Growth Factor Receptor.”J. Bio. Chem. 263:6233-6239 (1988.
Bayne et al., “The C Region of Human Insulin-Like Growth Factor (IGF) I is Required for High Affinity Binding to the Type 1 IGF Receptor.”J. Bio. Chem. 264(19):11004-11008 (1988).
Bayne et al., “The Roles of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Grow Factor-I to the Type I Insulin-Like Growth Factor Receptor.”J. Bio. Chem. 265(26):15648-15652 (Sep. 15, 1990).
Binoux, M., “Recent Data on Somatomedins (Insulin-Like Growth Factors).”Annales d'Endocrinologie(English Abstract Included) 41:157-192 (1980).
Blundell et al., “Insulin-Like Growth Factor: A Model for Tertiary Structure Accounting for Immunoreactivity and Receptor Binding.”Proc. Natl. Acad. Sci. USA75(1):180-184 (Jan. 1978).
Blundell et al., “Tertiary Structures, Receptor Binding, and Antigenicity of Insulinlike Growth Factors.”Federation Proc. 42:2592-2597 (1983).
Bondy, C., “Clinical Uses of Insulin-Like Growth Factor I.”Annals of Internal Medicine. 120:593-601 (1994).
Buckbinder et al., “Induction of the Growth Inhibitor IGF-Binding Protein 3 by p53.”Nature. 377:646-6 (Oct. 1995).
Cascieri et al., “Mutants of Human Insulin-Like Growth Factor I with Reduced Affinity for the Type 1 Insulin-Like Growth Factor Receptor.”Biochemistry27(9):3229-3233 (May 3, 1988).
Cascieri et al., “Structural Analogs of Human Insulin-Like Growth Factor (IGF) I with Altered Affinity for Type 2 IGF Receptors.”J. Bio. Chem. 264:2199-2202 (1989).
Cavanagh et al.Protein NMR Spectroscopy: Principles and Practice., New York:Academic Press, Inc. (199.
Clemmons and Van Wyk., “Somatomedin: Physiological Control and Effects on Cell Proliferation.”Handboo Exp. Pharmacol. 57:161-208 (1981).
Clemmons et al., “Competition for Binding to Insulin-Like Growth Factor (IGF) Binding Protein-2, 3, 4, and 5 by the IGFs and IGF Analogs.”Endocrinology. 131(2):890-895 (Aug. 1992).
Clemmons et al., “Discrete Alterations of the Insulin-Like Growth Factor I Molecule Which Alter Its Affinity for Insulin-Like Growth Factor-Binding Proteins Result in Changes in Bioactivity.”J. Bio. Chem. 265(21):12210-12216 (1990).
Clemmons et al., “The Role of Insulin-Like Growth Factors in the Nervous System.”Anal. NY Acad. Sci. USA692:10-21 (1993).
Clore et al., “Stereospecific Assignment of β-Methylene Protons in Larger Proteins Using 3D15N-Separated Hartmann-Hahn and13C-Separated Rotating Frame Overhauser Spectroscopy.”J. Biomol. NMR1:13-22 (1991).
Cohen et al., “Biological Effects of Prostate Specific Antigen as an Insulin-Like Growth Factor Binding Protein-3 Protease.”J. Endocrinology. 142:407-415 (1994).
Cohen et al., “Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells.”J. Clin. Endocrin.&Metab. 73:401-407 (1991).
Cohen et al., “The IGF Axis in the Prostate.”Horm.&Metab. Res. 26:81-84 (1994).
Cooke et al., “Solution Structure of Human Insulin-

Affiliated with

Also associated with

Rating

Crystallization of IGF-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystallization of IGF-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystallization of IGF-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3995186